Фармакогенетические аспекты профиля эффективности и безопасности блокаторов Н1 - гистаминовых рецепторов в терапии аллергических заболеваний

Today it is known that the second-generation Hl-antihistamines are substrates for the P-glycoprotein, that is encoded by the multiple drug resistance gene. The metabolism of the second-generation Hl-antihistamines involves a number of cytochrome P450 isoenzymes that encoded by the corresponding genes. All these noted genes are polymorphic, that can affect the activity of encoded proteins. Efflux alteration of second-generation Hl-antihistamines, as well as modifications in their biotransformation, can affect their efficacy and safety. The purpose of this review was to generalize current available information about pharmacogenetic characteristics of second-generation Hl-antihistamines and to suspect interindividual variability mechanisms of their efficacy and safety for allergic diseases.